Recursion Pharmaceuticals (RXRX) Stock Price

Financial Performance

Recursion Pharmaceuticals' revenue has shown a significant increase of 226.9% from the previous quarter and a modest year over year growth of 2.3%. However, both gross profit and operating income have shown negative figures with the former at -$7.1M and latter at -$191.4M, indicating high costs associated with their operations or potential investments into R&D for future growth. The EBITDA ratio stands at -12.98, which indicates that the company is not generating positive earnings before interest, taxes, depreciation, and amortization.

Stock Price

The stock price is currently trading at $5.49 which is up by 15.1% in the last month but down by -10.1% year over year indicating volatility in its performance. The RSI value is currently high at 72.83 suggesting that it might be overbought while the stock's 200-day moving average of $5.85 signifies that it's trading below its long-term trend.

Alternative Data Signals

The web traffic shows a decrease by -5.1%, potentially pointing to less online engagement or interest in the company compared to previous periods whereas job openings have also decreased slightly on both monthly and yearly basis suggesting either cost cutting measures or reduced expansion plans for now.

Around half of employees reported having a neutral business outlook with an estimated increase of 4% month over month but decrease of -26.8% YoY indicating mixed sentiment internally about future prospects.

Social media followership has seen significant growth especially on Twitter (82.% rise) which could indicate increasing brand awareness or investor interest.

Conclusion

Overall, based on the financial performance and alternative data signals, the analysis for Recursion Pharmaceuticals' stock appears to be neutral with a slight bearish tilt. The company has shown some positive signs in terms of revenue growth and social media engagement but high operational costs, negative profitability ratios and mixed sentiment among employees indicate potential challenges.

Note: This AI Stock Analysis is based on data as of October 04. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $5.49, will... Sign up to access price prediction.